Canopy Growth (NYSE:CGC) PT Lowered to $17.00

The highest sales estimate is $111.36 million and the lowest is $73.30 million. The business is expected to issue its next quarterly earnings report on Thursday, February 20th. On average, sell-side analysts expect that Becton Dickinson and Co will post 12.57 earnings per share for the current year. For the next year, analysts forecast that the firm will report earnings of ($0.40) per share, with EPS estimates ranging from ($0.55) to ($0.25). Zacks' sales averages are a mean average based on a survey of analysts that cover Canopy Growth.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Wednesday, October 30th. The marijuana producer reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by ($0.55). Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $1.69 million. Becton Dickinson and's revenue was up 4.1% compared to the same quarter previous year.

A number of analysts recently commented on K shares. TheStreet raised Kellogg from a "c+" rating to a "b-" rating in a research note on Monday, August 12th. Credit Suisse Group set a $60.00 price objective on Kellogg and gave the company a "hold" rating in a research note on Tuesday, September 10th.

Canopy Growth (NYSE:CGC) had its target price cut by Compass Point from $24.00 to $17.00 in a research report report published on Friday, November 15th, The Fly reports.

Other equities research analysts have also recently issued research reports about the stock.

CGC stock is in the green to finish the week after Canopy Growth (TSX:WEED) (NYSE:CGC) provided an update on its rollout of cannabis 2.0 products over the coming weeks. 2,980,579 shares of the company traded hands, compared to its average volume of 6,558,448. The stock has a fifty day simple moving average of $244.13 and a 200-day simple moving average of $233.72. The firm has a market capitalization of $69.91 billion, a PE ratio of 22.32, a P/E/G ratio of 1.82 and a beta of 1.07. Canopy Growth has a fifty-two week low of $13.81 and a fifty-two week high of $52.74. The ex-dividend date is Monday, December 9th. Becton Dickinson and's payout ratio is presently 26.37%. Also, major shareholder Ronald O. Perelman purchased 1,369,863 shares of the company's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $97.27, for a total value of $181,894.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The stock was sold at an average price of $256.63, for a total value of $7,666,307.99. The disclosure for this sale can be found here. Insiders own 3.10% of the company's stock. Price T Rowe Associates Inc. TCG Advisors LP raised its holdings in shares of Canopy Growth by 77.3% during the 2nd quarter. Pictet Asset Management Ltd. now owns 78,871 shares of the marijuana producer's stock worth $1,808,000 after buying an additional 1,300 shares during the period. Penserra Capital Management LLC bought a new stake in Canopy Growth during the 3rd quarter worth approximately $359,000. Finally, USA Mutuals Advisors Inc. bought a new position in Canopy Growth in the 3rd quarter valued at $790,000. Prime Capital Investment Advisors LLC now owns 1,563 shares of the marijuana producer's stock worth $36,000 after acquiring an additional 1,155 shares during the last quarter. Finally, Virtu Financial LLC raised its position in shares of vTv Therapeutics by 162.4% in the 3rd quarter. Invesco Ltd. now owns 760,782 shares of the technology company's stock worth $181,667,000 after purchasing an additional 331,459 shares during the last quarter.

MSCI Inc, together with its subsidiaries, provides investment decision support tools for the clients to manage their investment processes worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Latest News